Domvanalimab - Arcus Biosciences
Alternative Names: AB 154; GS-0154Latest Information Update: 30 Jan 2025
Price :
$50 *
At a glance
- Originator Abmuno Therapeutics
- Developer Arcus Biosciences; AstraZeneca; Gilead Sciences; University of Texas Southwestern Medical Center; Yale University
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Gastrointestinal cancer; Non-small cell lung cancer
- Phase II Liver cancer
- Phase I/II Cancer; Pancreatic cancer
- No development reported Glioblastoma
Most Recent Events
- 24 Jan 2025 Hospices Civils de Lyon plans to initiate a phase II (IMMUNORARE5) trial for rare cancers (Combination therapy, late-stage disease) in France (IV) (NCT06790706)
- 11 Dec 2024 Gilead Sciences plans a phase II VELOCITY-HNSCC trial for Squamous cell cancer (Combination therapy, Late-stage disease, Second-line theraoy or greater) in unknown location (SC) (NCT06727565)
- 06 Nov 2024 Efficacy and adverse events data from the phase III trial in Non-small cell lung cancer released by Arcus Biosciences